Remdesivir Use Compared With Supportive Care in Hospitalized Patients With Severe COVID-19: A Single-Center Experience.

ABSTRACT:

Background

The US Food and Drug Administration issued an Emergency Use Authorization for remdesivir use in patients with severe COVID-19.

Methods

We utilized data from 2 quaternary acute care hospitals. The outcomes of interest were the impact of remdesivir on in-hospital death by day 28 and time to recovery, clinical improvement, and discharge. We utilized Cox proportional hazards models and stratified log-rank tests.

Results

Two hundred twenty-four patients were included in the study. The median age was 59 years; 67.0% were male; 17/125 patients (13.6%) who received supportive care and 7/99 patients (7.1%) who received remdesivir died. The unadjusted risk for 28-day in-hospital death was lower for patients who received remdesivir compared with patients who received

SUBMITTER: Kalligeros M 

PROVIDER: S-EPMC7454852 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature